Login to Your Account

Genmab Licenses HuMax-TAC To Serono In Deal Worth Up To $40M

By Cormac Sheridan

Wednesday, May 4, 2005
Genmab A/S partnered a preclinical project in organ transplant rejection and T-cell mediated disorders, HuMax-TAC, with Serono SA in a deal that could be worth up to $40 million in up-front and milestone payments, plus royalties on eventual product sales. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription